Pathogenesis of chronic cardiorenal syndrome: Is there a role for oxidative stress?

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 23011-23032

  Rubattu, Speranza ^a,b   Mennuni, Silvia ^a   Testa, Marco ^a   Mennuni, Mara ^c   Pierelli, Giorgia ^a   Pagliaro, Beniamino ^a   Gabriele, Erica ^a   Coluccia, Roberta ^a   Autore, Camillo ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Heart failure; Inflammation; Mitochondrial dysfunction; Oxidative stress; Renal failure; Renin angiotensin aldosterone system; Sympathetic nervous system

Indexed keywords

ADENYLATE KINASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; MITOQ; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE PROTEIN 2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE PROTEIN 3; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE PROTEIN 4; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE PROTEIN 5; PHOSPHOLIPASE A2; PYRUVATE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STRESS ACTIVATED PROTEIN KINASE; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA1; UBIQUINONE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; AEROBIC METABOLISM; CARDIORENAL SYNDROME; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FATTY ACID OXIDATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEART FAILURE; HEART FUNCTION; HUMAN; KIDNEY FAILURE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

CARDIO-RENAL SYNDROME; CHRONIC DISEASE; HUMANS; INFLAMMATION; MITOCHONDRIA; MYOCARDIUM; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84888117591     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141123011     Document Type: Review

References (146)

1. Ronco, C.; House, A.A.; Haapio, M. Cardio-renal syndrome: Refining the definition of a complex symbiosis gone wrong. Intensiv. Care Med. 2008, 34, 957-962.
2. Ronco, C.; Ronco, F. Cardio-renal syndromes: A systematic approach for consensus definition and classification. Heart Fail Rev. 2012, 17, 151-160.
3. Ronco, C.; McCullough, P.; Anker, S.D.; Anand, I.; Aspromonte, N.; Bagshaw, S.M.; Bellomo, R.; Berl, T.; Bobek, I.; Cruz, D.N., et al. Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 2010, 31, 703-711.
4. Guyton, A.C. The surprising kidney-fluid mechanism for pressure control-its infinite gain! Hypertension 1990, 16, 725-730.
5. Lindner, A.; Charra, B.; Sherrard, D.J.; Scribner, B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 1974, 290, 697-701.
6. Oh, J.; Wunsch, R.; Turzer, M.; Bahner, M.; Raggi, P.; Querfeld, U.; Mehls, O.; Schaefer, F. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002, 106, 100-105.
7. Rambausek, M.; Ritz, E.; Mall, G.; Mehls, O.; Katus, H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int. 1985, 28, 775-782.
8. Törnig, J.; Gross, M.L.; Simonaviciene, A.; Mall, G.; Ritz, E.; Amann, K. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J. Am. Soc. Nephrol. 1999, 10, 77-83.
9. Safar, M.E.; London, G.M.; Plante, G.E. Arterial stiffness and kidney function. Hypertension 2004, 43, 163-168.
10. Goodman, W.G.; Goldin, J.; Kuizon, B.D.; Yoon, C.; Gales, B.; Sider, D.; Wang, Y.; Chung, J.; Emerick, A.; Greaser, L., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000, 342, 1478-1483.
11. Sies, H. Oxidative stress: Oxidants and antioxidants. Exp. Physiol. 1997, 82, 291-295.
12. Hafstad, A.D.; Nabeebaccus, A.A.; Shah, A.M. Novel aspects of ROS signalling in heart failure. Basic Res. Cardiol. 2013, 108, 359.
13. Schramm, A.; Matusik, P.; Osmenda, G.; Guzik, T.J. Targeting NADPH oxidases in vascular pharmacology. Vasc. Pharmacol. 2012, 56, 216-231.
14. Sirker, A.; Zhang, M.; Shah, A.M. NADPH oxidases in cardiovascular disease: Insights from in vivo models and clinical studies. Basic Res. Cardiol. 2011, 106, 735-747.
15. Modlinger, P.S.; Wilcox, C.S.; Aslam, S. Nitric oxide, oxidative stress, and progression of chronic renal failure. WB Saunders. Semin. Nephrol. 2004, 24, 354-365.
16. Maack, C.; Böhm, M. Targeting mitochondrial oxidative stress in heart failure. Throttling the afterburner. J. Am. Coll. Cardiol. 2011, 58, 83-86.
17. Matsushima, S.; Ide, T.; Yamato, M.; Matsusaka, H.; Hattori, F.; Ikeuchi, M.; Kubota, T.; Sunagawa, K.; Hasegawa, Y.; Kurihara, T., et al. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2006, 113, 1779-1786.
18. Osterholt, M.; Nguyen, T.D.; Schwarzer, M.; Doenst, T. Alterations in mitochondrial function in cardiac hypertrophy and heart failure. Heart Fail Rev. 2013, 18, 645-656.
19. Graziewicz, M.A.; Day, B.J.; Copeland, W.C. The mitochondrial DNA polymerase as a target of oxidative damage. Nucleic Acids Res. 2002, 30, 2817-2824.
20. Chen, L.; Knowlton, A.A. Mitochondrial dynamics in heart failure. Congest. Heart Fail 2010, 17, 257-261.
21. Stanley, W.C.; Chandler, M.P. Energy metabolism in the normal and failing heart: Potential for therapeutic interventions. Heart Fail Rev. 2002, 7, 115-130.
22. Beer, M.; Seyfarth, T.; Sandstede, J.; Landschütz, W.; Lipke, C.; Köstler, H.; von Kienlin, M.; Harre, K.; Hahn, D.; Neubauer, S. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J. Am. Coll. Cardiol. 2002, 40, 1267-1274.
23. Conway, M.A.; Allis, J.; Ouwerkerk, R.; Niioka, T.; Rajagopalan, B.; Radda, G.K. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991, 338, 973-976.
24. Tian, R.; Nascimben, L.; Kaddurah-Daouk, R.; Ingwall, J.S. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J. Mol. Cell. Cardiol. 1996, 28, 755-765.
25. Kato, T.; Niizuma, S.; Inuzuka, Y.; Kawashima, T.; Okuda, J.; Tamaki, Y.; Iwanaga, Y.; Narazaki, M.; Matsuda, T.; Soga, T., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail 2010, 3, 420-430.
26. Lei, B., Lionetti, V.; Young, M.E.; Chandler, M.P.; d'Agostino, C.; Kang, E.; Altarejos, M.; Matsuo, K.; Hintze, T.H.; Stanley, W.C. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J. Mol. Cell. Cardiol. 2004, 36, 567-576.
27. Katz, A.M.; Konstam, M.A. Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2009.
28. Rosca, M.G.; Vazquez, E.J.; Kerner, J.; Parland, W.; Chandler, M.P.; Stanley, W.; Sabbah, H.N.; Hoppel, C.L. Cardiac mitochondria in heart failure: Decrease in respirasomes and oxidative phosphorylation. Cardiovasc. Res. 2008, 80, 30-39.
29. Scheubel, R.J.; Tostlebe, M.; Simm, A.; Rohrbach, S.; Prondzinsky, R.; Gellerich, F.N.; Silber, R.E.; Holtz, J. Dysfunction of mitochondrial respiratory chain complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J. Am. Coll. Cardiol. 2002, 40, 2174-2181.
30. Lemieux, H.; Semsroth, S.; Antretter, H.; Höfer, D.; Gnaiger, E. Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int. J. Biochem. Cell Biol. 2011, 43, 1729-1738.
31. Buchwald, A.; Till, H.; Unterberg, C.; Oberschmidt, R.; Figulla, H.R.; Wiegand, V. Alterations of the mitochondrial respiratory chain in human dilated cardiomyopathy. Eur. Heart J. 1990, 11, 509-516.
32. Marin-Garcia, J.; Goldenthal, M.J.; Moe, G.W. Mitochondrial pathology in cardiac failure. Cardiovasc. Res. 2001, 49, 17-26.
33. Rosca, M.G.; Hoppel, C.L. New aspects of impaired mitochondrial function in heart failure. J. Bioenerg. Biomembr. 2009, 41, 107-112.
34. Kimura, S.; Zhang, G.X.; Nishiyama, A.; Shokoji, T.; Yao, L.; Fan, Y.Y.; Rahman, M.; Suzuki, T.; Maeta, H.; Abe, Y. Role of NAD (P) H oxidase-and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005, 45, 860-866
35. Dai, D.F.; Johnson, S.C.; Villarin, J.J.; Chin, M.T.; Nieves-Cintrón, M.; Chen, T.; Marcinek, D.J.; Dorn, G.W., II.; Kang, Y.J.; Prolla, T.A., et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Gαq overexpression-induced heart failure. Novelty and significance. Circ. Res. 2011, 108, 837-846.
36. Marín-García, J.; Akhmedov, A.T.; Moe, G.W. Mitochondria in heart failure: The emerging role of mitochondrial dynamics. Heart Fail Rev. 2013, 18, 439-456.
37. Rosca, M.G.; Hoppel, C.L. Mitochondria in heart failure. Cardiovasc. Res. 2010, 88, 40-50.
38. Siwik, D.A.; Pagano, P.J.; Colucci, W.S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 2001, 280, C53-C60.
39. Spinale, F.G.; Coker, M.L.; Thomas, C.V.; Walker, J.D.; Mukherjee, R.; Hebbar, L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure relation to ventricular and myocyte function. Circ. Res. 1998, 82, 482-495.
40. Danial, N.N.; Korsmeyer, S.J. Cell death: Critical control points. Cell 2004, 116, 205-219.
41. Li, L.Y.; Luo, X.; Wang, X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001, 412, 95-99.
42. Kwon, S.H.; Pimentel, D.R.; Remondino, A.; Sawyer, D.B.; Colucci, W.S. H2O2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J. Mol. Cell. Cardiol. 2003, 35, 615-621.
43. Chaanine, A.H.; Jeong, D.; Liang, L.; Chemaly, E.R.; Fish, K.; Gordon, R.E.; Hajjar, R.J. JNK modulates FOXO3a for the expression of the mitochondrial death and mitophagy marker BNIP3 in pathological hypertrophy and in heart failure. Cell Death Dis. 2012, 3, 265.
44. Chiong, M.; Wang, Z.V.; Pedrozo, Z.; Cao, D.J.; Troncoso, R.; Ibacache, M.; Criollo, A.; Nemchenko, A.; Hill, J.A.; Lavandero, S. Cardiomyocyte death: Mechanisms and translational implications. Cell Death Dis. 2011, 2, e244.
45. Vacek, T.P.; Vacek, J.C.; Tyagi, S.C. Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling. Arch. Physiol. Biochem. 2012, 118, 31-42.
46. Gorin, Y.; Ricono, J.; Wagner, B.; Kim, N.; Bhandari, B.; Choudhury, G.; Abboud, H. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem. J. 2004, 381, 231-239.
47. Hannken, T.; Schroeder, R.; Stahl, R.A.; Wolf, G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals1. Kidney Int. 1998, 54, 1923-1933.
48. Lodha, S.; Dani, D.; Mehta, R.; Bhaskaran, M.; Reddy, K.; Ding, G.; Singhal, P.C. Angiotensin II-induced mesangial cell apoptosis: Role of oxidative stress. Mol. Med. 2002, 8, 830-840.
49. López, B.; Salom, M.G.; Arregui, B.; Valero, F.; Fenoy, F.J. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 2003, 42, 1150-1156.
50. Miyata, K.; Rahman, M.; Shokoji, T.; Nagai, Y.; Zhang, G.X.; Sun, G.P.; Kimura, S.; Yukimura, T.; Kiyomoto, H.; Kohno, M., et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J. Am. Soc. Nephrol. 2005, 16, 2906-2912.
51. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007, 87, 245-313.
52. Nagase, M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin. Exp. Nephrol. 2010, 14, 303-314.
53. Zou, A.P.; Li, N.; Cowley, A.W. Production and actions of superoxide in the renal medulla. Hypertension 2001, 37, 547-553.
54. Chabrashvili, T.; Tojo, A.; Onozato, M.L.; Kitiyakara, C.; Quinn, M.T.; Fujita, T.; Welch, W.J.; Wilcox, C.S. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002, 39, 269-274.
55. Geiszt, M.; Kopp, J.B.; Várnai, P.; Leto, T.L. Identification of renox, an NAD (P) H oxidase in kidney. Proc. Natl. Acad. Sci. USA 2000, 97, 8010-8014.
56. Shiose, A.; Kuroda, J.; Tsuruya, K.; Hirai, M.; Hirakata, H.; Naito, S.; Hattori, M.; Sakaki, Y.; Sumimoto, H. A novel superoxide-producing NAD (P) H oxidase in kidney. J. Biol. Chem. 2001, 276, 1417-1423.
57. Cheng, G.; Cao, Z.; Xu, X.; Meir, E.G.V.; Lambeth, J.D. Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 2001, 269, 131-140.
58. Vaziri, N.D.; Dicus, M.; Ho, N.D.; Boroujerdi-Rad, L.; Sindhu, R.K. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 2003, 63, 179-185.
59. Gorin, Y.; Ricono, J.M.; Kim, N.H.; Bhandari, B.; Choudhury, G.G.; Abboud, H. E. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am. J. Physiol. Ren. Physiol. 2003, 285, F219-F229.
60. Wilcox, C.S. Redox regulation of the afferent arteriole and tubuloglomerular feedback. Acta Physiol. Scand. 2003, 179, 217-223.
61. Raij, L. Nitric oxide and cardiovascular and renal effects. Osteoarthr. Cartil. 2008, 16, S21-S26.
62. Liaudet, L.; Soriano, F.G.; Szabó, C. Biology of nitric oxide signaling. Crit. Care Med. 2000, 28, N37-N52.
63. Schnackenberg, C.G. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282, R335-R342.
64. Rhyu, D.Y.; Yang, Y.; Ha, H.; Lee, G.T.; Song, J.S.; Uh, S.T.; Lee, H.B. Role of reactive oxygen species in TGF-β1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J. Am. Soc. Nephrol. 2005, 16, 667-675.
65. Thiery, J.P.; Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7, 131-142.
66. Wolf, G.; Wenzel, U.; Hannken, T.; Stahl, R.A. Angiotensin II induces p27Kip1 expression in renal tubules in vivo: Role of reactive oxygen species. J. Mol. Med. 2001, 79, 382-389.
67. Napoli, C.; Casamassimi, A.; Crudele, V.; Infante, T.; Abbondanza, C. Kidney and heart interactions during cardiorenal syndrome: A molecular and clinical pathogenic framework. Future Cardiol. 2011, 7, 485-497.
68. Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420-1428.
69. Yoshikawa, M.; Hishikawa, K.; Marumo, T.; Fujita, T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J. Am. Soc. Nephrol. 2007, 18, 58-65.
70. Ng, Y.Y.; Huang, T.P.; Yang, W.C.; Chen, Z.P.; Yang, A.H.; Mu, W.; Nikolic-Paterson, D.J.; Atkins, R.C.; Lan, H.Y. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int. 1998, 54, 864-876.
71. Iwano, M.; Plieth, D.; Danoff, T.M.; Xue, C.; Okada, H.; Neilson, E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Investig. 2002, 110, 341-350.
72. Yang, J.; Liu, Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol. 2001, 159, 1465-1475.
73. Böttinger, E.P.; Bitzer, M. TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 2002, 13, 2600-2610.
74. Dorsam, G.; Taher, M.M.; Valerie, K.C.; Kuemmerle, N.B.; Chan, J.C.; Franson, R.C. Diphenyleneiodium chloride blocks inflammatory cytokine-induced up-regulation of group IIA phospholipase A2 in rat mesangial cells. J. Pharmacol. Exp. Ther. 2000, 292, 271-279.
75. Cui, X.L.; Douglas, J.G. Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. Proc. Natl. Acad. Sci. USA 1997, 94, 3771-3776.
76. Satriano, J.A.; Shuldiner, M.; Hora, K.; Xing, Y.; Shan, Z.; Schlondorff, D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J. Clin. Investig. 1993, 92, 1564-1571.
77. Feng, L.; Xia, Y.; Garcia, G.E.; Hwang, D.; Wilson, C.B. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J. Clin. Investig. 1995, 95, 1669-1675.
78. Di Castro, S.; Scarpino, S.; Marchitti, S.; Bianchi, F.; Stanzione, R.; Cotugno, M.; Sironi, L.; Gelosa, P.; Duranti, E.; Ruco, L., et al. Differential modulation of UCP2 in kidneys of stroke-prone spontaneously hypertensive rats under high salt/low potassium diet. Hypertension 2013, 61, 534-541.
79. Mattiasson, G.; Sullivan, P.G. The emerging functions of UCP2 in health, disease, and therapeutics. Antioxid. Redox Signal. 2006, 8, 1-38.
80. Yoshida, T.; Kato, K.; Fujimaki, T.; Yokoi, K.; Oguri, M.; Watanabe, S.; Metoki, N.; Yoshida, H.; Satoh, K.; Aoyagi, Y., et al. Association of genetic variants with chronic kidney disease in Japanese individuals. Clin. J. Am. Soc. Nephrol. 2009, 4, 883-890.
81. Metra, M.; Davison, B.; Bettari, L.; Sun, H.; Edwards, C.; Lazzarini, V.; Piovanelli, B.; Carubelli, V.; Bugatti, S.; Lombardi, C., et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ. Heart Fail 2012, 5, 54-62.
82. Shlipak, M.G.; Fried, L.F.; Crump, C.; Bleyer, A.J.; Manolio, T.A.; Tracy, R.P.; Furberg, C.D.; Psaty, B.M. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003, 107, 87-92.
83. Stuveling, E.M.; Hillege, H.L.; Bakker, S.J.; Gans, R.O.; de Jong, P.E.; de Zeeuw, D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003, 63, 654-661.
84. Ikizler, T.A.; Morrow, J.D.; Roberts, L.J.; Evanson, J.A.; Becker, B.; Hakim, R.M.; Shyr, Y.; Himmelfarb, J. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin. Nephrol. 2002, 58, 190-197.
85. Dounousi, E.; Papavasiliou, E.; Makedou, A.; Ioannou, K.; Katopodis, K.P.; Tselepis, A.; Siamopoulos, K.C.; Tsakiris, D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney Dis. 2006, 48, 752-760.
86. Oberg, B.P.; McMenamin, E.; Lucas, F.L.; McMonagle, E.; Morrow, J.; Ikizler, T.A.; Himmelfarb, J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004, 65, 1009-1016.
87. Nerpin, E.; Helmersson-Karlqvist, J.; Risérus, U.; Sundström, J.; Larsson, A.; Jobs, E.; Basu, S.; Ingelsson, E.; Arnlöv, J. Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: A cross-sectional study. BMC Res. Notes 2012, 5, 537.
88. El Nahas, M. Cardio-Kidney-Damage: A unifying concept. Kidney Int. 2010, 78, 14-18.
89. Chaney, E.; Shaw, A. Pathophysiology of fluid retention in heart failure. Contrib. Nephrol. 2010, 164, 46-53.
90. Colombo, P.C.; Ganda, A.; Lin, J.; Onat, D.; Harxhi, A.; Iyasere, J.E.; Uriel, N.; Cotter, G. Inflammatory activation: Cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012, 17, 177-190.
91. Bongartz, L.G.; Cramer, M.J.; Doevendans, P.A.; Joles, J.A.; Braam, B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur. Heart J. 2005, 26, 11-17.
92. Bongartz, L.G.; Braam, B.; Gaillard, C.A.; Cramer, M.J.; Goldschmeding, R.; Verhaar, M.C.; Doevendans, P.A.; Joles, J.A. Target organ cross talk in cardiorenal syndrome: Animal models. Am. J. Physiol. Ren. Physiol. 2012, 303, F1253-F1263.
93. Griendling, K.K.; Minieri, C.A.; Ollerenshaw, J.D.; Alexander, R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994, 74, 1141-1148.
94. Ushio-Fukai, M.; Zafari, A.M.; Fukui, T.; Ishizaka, N.; Griendling, K.K. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 1996, 271, 23317-23321.
95. Chabrashvili, T.; Kitiyakara, C.; Blau, J.; Karber, A.; Aslam, S.; Welch, W.J.; Wilcox, C.S. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285, R117-R124.
96. Nakagami, H.; Takemoto, M.; Liao, J.K. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 2003, 35, 851-859.
97. Heymes, C.; Bendall, J.K.; Ratajczak, P.; Cave, A.C.; Samuel, J.L.; Hasenfuss, G.; Shah, A.M. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll. Cardiol. 2003, 41, 2164-2171.
98. Tojo, A.; Onozato, M.L.; Kobayashi, N.; Goto, A.; Matsuoka, H.; Fujita, T. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002, 40, 834-839.
99. Hornig, B.; Landmesser, U.; Kohler, C.; Ahlersmann, D.; Spiekermann, S.; Christoph, A.; Tatge, H.; Drexler, H. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease role of superoxide dismutase. Circulation 2001, 103, 799-805.
100. Ruiz-Ortega, M.; Lorenzo, O.; Egido, J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 2000, 57, 2285-2298.
101. Pueyo, M.E.; Gonzalez, W.; Nicoletti, A.; Savoie, F.; Arnal, J.F.; Michel, J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 645-651.
102. Klein, I.H.; Ligtenberg, G.; Oey, P.L.; Koomans, H.A.; Blankestijn, P.J. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J. Am. Soc. Nephrol. 2003, 14, 425-430.
103. Jackson, G.; Gibbs, C.R.; Davies, M.K.; Lip, G.Y.H. ABC of heart failure: Pathophysiology. BMJ 2000, 320, 167-170.
104. Amin, J.K.; Xiao, L.; Pimental, D.R.; Pagano, P.J.; Singh, K.; Sawyer, D.B.; Colucci, W.S. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J. Mol. Cell. Cardiol. 2001, 33, 131-139.
105. Bleeke, T.; Zhang, H.; Madamanchi, N.; Patterson, C.; Faber, J.E. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ. Res. 2004, 94, 37-45.
106. Bianchi, P.; Séguélas, M.H.; Parini, A.; Cambon, C. Activation of pro-apoptotic cascade by dopamine in renal epithelial cells is fully dependent on hydrogen peroxide generation by monoamine oxidases. J. Am. Soc. Nephrol. 2003, 14, 855-862.
107. Liao, J.; Keiser, J.A.; Scales, W.E.; Kunkel, S.L.; Kluger, M.J. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1995, 268, R896-R901.
108. Oddis, C.V.; Simmons, R.L.; Hattler, B.G.; Finkel, M.S. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 1995, 269, H2044-H2050.
109. Arici, M.; Walls, J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001, 59, 407-414.
110. Zebrack, J.S.; Anderson, J.L.; Beddhu, S.; Horne, B.D.; Bair, T.L.; Cheung, A.; Muhlestein, J.B. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency? J. Am. Coll. Cardiol. 2003, 42, 57-63.
111. Irish, A. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998, 137, 133-139.
112. Testa, M.; Yeh, M.; Lee, P.; Fanelli, R.; Loperfido, F.; Berman, J.W.; LeJemtel, T.H. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 1996, 28, 964-971.
113. Sanchez-Lozada, L.G.; Tapia, E.; Johnson, R.J.; Rodriguez-Iturbe, B.; Herrera-Acosta, J. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int. 2003, 64, S9-S14.
114. Niijima, A.; Hori, T.; Aou, S.; Oomura, Y. The effects of interleukin-1β on the activity of adrenal, splenic and renal sympathetic nerves in the rat. J. Auton. Nerv. Syst. 1991, 36, 183-192.
115. Wassmann, S.; Stumpf, M.; Strehlow, K.; Schmid, A.; Schieffer, B.; Böhm, M.; Nickenig, G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ. Res. 2004, 94, 534-541.
116. Tsutamoto, T.; Hisanaga, T.; Wada, A.; Maeda, K.; Ohnishi, M.; Fukai, D.; Mabuchi, N.; Sawaki, M.; Kinoshita, M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 1998, 31, 391-398.
117. Anker, S.D.; Egerer, K.R.; Volk, H.D.; Kox, W.J.; Poole-Wilson, P.A.; Coats, A.J. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am. J. Cardiol. 1997, 79, 1426-1430.
118. Kawai, M.; Naruse, K.; Komatsu, S.; Kobayashi, S.; Nagino, M.; Nimura, Y.; Sokabe, M. Mechanical stress-dependent secretion of interleukin 6 by endothelial cells after portal vein embolization: Clinical and experimental studies. J. Hepatol. 2002, 37, 240-246.
119. McMurray, J.J. CONSENSUS to EMPHASIS: The overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur. J. Heart Fail 2011, 13, 929-936.
120. Kim, Y.S.; Greenberg, B. Update on renin-angiotensin-aldosterone blockade in heart failure. Curr. Treat. Options Cardiovasc. Med. 2009, 11, 455-466.
121. Konstam, M.A.; Rousseau, M.F.; Kronenberg, M.W.; Udelson, J.E.; Melin, J.; Stewart, D.; Dolan, N.; Edens, T.R.; Ahn, S.; Kinan, D., et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992, 86, 431-438.
122. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Grunfeld, J.P.; Keane, W.F.; Kurokawa, K.; McGill, J.B.; Mitch, W.E.; Parving, H.H.; Remuzzi, G., et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J. Renin Angiotensin Aldosterone Syst. 2000, 1, 328-335.
123. Granger, C.B.; McMurray, J.J.; Yusuf, S.; Held, P.; Michelson, E.L.; Olofsson, B.; Ostergren, J.; Pfeffer, M.A.; Swedberg, K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003, 362, 772-776.
124. Parving, H.H.; Lehnert, H.; Bröchner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001, 345, 870-878.
125. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345, 851-860.
126. Maschio, G.; Alberti, D.; Janin, G.; Locatelli, F.; Mann, J.F.; Motolese, M.; Ponticelli, C.; Ritz, E.; Zucchelli, P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N. Engl. J. Med. 1996, 334, 939-945.
127. Hou, F.F.; Zhang, X.; Zhang, G.H.; Xie, D.; Chen, P.Y.; Zhang, W.R.; Jiang, J.P.; Liang, M.; Wang, G.B.; Liu, Z.R., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006, 354, 131-140.
128. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348, 1309-1321.
129. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999, 341, 709-717.
130. Eichhorn, E.J.; Heesch, C.M.; Barnett, J.H.; Alvarez, L.G.; Fass, S.M.; Grayburn, P.A.; Hatfield, B.A.; Marcoux, L.G.; Malloy, C.R. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 1994, 24, 1310-1320.
131. Sawyer, D.B.; Colucci, W.S. Mitochondrial oxidative stress in heart failure "oxygen wastage" revisited. Circ. Res. 2000, 86, 119-120.
132. Guzik, T.J.; Griendling, K.K. NADPH oxidases: Molecular understanding finally reaching the clinical level? Antioxid. Redox Signal. 2009, 11, 2365-2370.
133. Guzik, T.J.; Harrison, D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 2006, 11, 524-533.
134. Wind, S.; Beuerlein, K.; Eucker, T.; Muller, H.; Scheurer, P.; Armitage, M.E.; Ho, H.; Schmidt, H.H.; Wingler, K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 2010, 161, 885-898.
135. Stolk, J.; Hiltermann, T.J.; Dijkman, J.H.; Verhoeven, A.J. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol. 1994, 11, 95-102.
136. Cayatte, A.J.; Rupin, A.; Oliver-Krasinski, J.; Maitland, K.; Sansilvestri-Morel, P.; Boussard, M.F.; Wierzbicki, M.; Verbeuren, T.J.; Cohen, R.A. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets NADPH oxidase. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1577-1584.
137. Xu, S.; Jiang, B.; Hou, X.; Shi, C.; Bachschmid, M.M.; Zang, M.; Verbeuren, T.J.; Cohen, R.A. High-fat diet increases and the polyphenol, S17834, decreases acetylation of the sirtuin-1-dependent lysine-382 on p53 and apoptotic signaling in atherosclerotic lesion-prone aortic endothelium of normal mice. J. Cardiovasc. Pharmacol. 2011, 58, 263-271.
138. Rey, F.E.; Cifuentes, M.E.; Kiarash, A.; Quinn, M.T.; Pagano, P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res. 2001, 89, 408-414.
139. Dai, D.F.; Hsieh, E.J.; Chen, T.; Menendez, L.G.; Basisty, N.B.; Tsai, L.; Beyer, R.P.; Crispin, D.A.; Shulman, N.J.; Szeto, H.H., et al. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circ. Heart Fail 2013, 6, 1067-1076.
140. Bayeva, M.; Gheorghiade, M.; Ardehali, H. Mitochondria as a therapeutic target in heart failure. J. Am. Coll. Cardiol. 2013, 61, 599-610.
141. McQueen, M.J.; Lonn, E.; Gerstein, H.C.; Bosch, J.; Yusuf, S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand. J. Clin. Lab. Investig. 2005, 65, 143-156.
142. Collins, R.; Armitage, J.; Parish, S.; Sleight, P.; Peto, R. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360, 23-33.
143. Smith, R.A.; Porteous, C.M.; Gane, A.M.; Murphy, M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. USA 2003, 100, 5407-5412.
144. Adlam, V.J.; Harrison, J.C.; Porteous, C.M.; James, A.M.; Smith, R.A.; Murphy, M.P.; Sammut, I.A. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005, 19, 1088-1095.
145. Neuzil, J.; Widén, C.; Gellert, N.; Swettenham, E.; Zobalova, R.; Dong, L.F.; Wang, X.F.; Lidebjer, C.; Dalen, H.; Headrick, J.P., et al. Mitochondria transmit apoptosis signalling in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury. Redox Rep. 2007, 12, 148-162.
146. Parajuli, N.; Campbell, L.H.; Marine, A.; Brockbank, K.G.; MacMillan-Crow, L.A. MitoQ blunts mitochondrial and renal damage during cold preservation of porcine kidneys. PLoS One 2012, 7, e48590.